Dr. Samuel Denmeade on Bipolar Androgen Therapy for Prostate Cancer

[madman]

* This approach involves administering high doses of testosterone, which has shown significant improvement in 30% of patients, enhancing strength, energy, and sexual function

* their research uses blood-based DNA markers to predict which patients will respond best, aiming to personalize treatment and switch between high and low testosterone levels to prevent cancer resistance

Dr. Samuel Denmeade, an oncologist at Johns Hopkins, discusses bipolar androgen therapy, a novel treatment for prostate cancer patients resistant to standard hormone therapy. This approach involves administering high doses of testosterone, which has shown significant improvement in 30% of patients, enhancing strength, energy, and sexual function. Dr. Denmeade explains how their research uses blood-based DNA markers to predict which patients will respond best, aiming to personalize treatment and switch between high and low testosterone levels to prevent cancer resistance.

 

[madman]

Identifying Blood-Based Markers for Optimized Bipolar Androgen Therapy in mCRPC

Samuel Denmeade, MD, of Johns Hopkins University School of Medicine, highlights his research on blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial. This research was presented as a late-breaking abstract at the 2024...

www.excelmale.com

 

[Vince]

Could More Testosterone Be the Hidden Key to Fighting Prostate Cancer?

Androgen deprivation therapy (ADT) has been the bedrock of treatment for advanced prostate cancer for more than half a century. But investigators at Johns Hopkins are rethinking it – in a way that sounds counterintuitive – and driving new approaches to tackle treatment resistance. They’re...

www.pcf.org